Cardiovascular Diseases Clinical Trial
To conduct a multicenter prevalence survey for characterizing pathologically the extent of atherosclerosis in the aortas and coronary arteries of young persons dying from accidental causes, suicide, or homicide.
BACKGROUND:
The International Atherosclerosis Project (IAP) quantified atherosclerosis of the aorta and
coronary arteries in over 31,000 persons age 10 to 69 who died between 1960 and 1965 in
fifteen cities and countries throughout the world. The IAP established that the average
severity of atherosclerosis differed widely in many parts of the world and that the
differences correlated with mortality from ischemic heart disease. It also demonstrated that
the fatty streaks of childhood were prevalent and severe in both boys and girls. Fibrous
plaques generally first appeared between the ages of 20 and 30 and in proportion to the
prevalence of ischemic disease in the adult population. Since the results of the IAP were
first published in 1968, research into atherosclerosis has changed greatly from gross and
microscopic morphological methods to manipulation of experimental animals, in vitro culture
of arterial wall cells, and the application of micro-chemical, physical chemical, and
immunological techniques to tissues.
The use of these newer techniques made it possible to test the hypothesis that a series of
changes in the fatty streak between the ages of fifteen and twenty-five lead to the typical
fibrous plaque and to test the hypothesis that lesions other than fatty streaks precede and
may progress to fibrous plaques. The study also tested associations of the established risk
factors for atherosclerosis with early stages of lesion progression as seen in young
persons.
The protocol for this study served as the basis of the protocol developed by the World
Health Organization (WHO) Committee on Pathobiological Determinants of Atherosclerosis in
Youth. It was planned to incorporate this study into the WHO study so that cross-cultural
and geographic factors could be evaluated in populations with higher and lower incidence of
atherosclerosis.
DESIGN NARRATIVE:
A common protocol was followed for collecting risk factor data and coronary arteries and
aortas from approximately 1,000 autopsies per year for three years. Specimens were collected
and preserved in a standardized way at each collection center. Data management and
statistical analysis were conducted at the University of Texas in San Antonio. The unit at
Louisiana State University was composed of three central laboratories: the lipid
biochemistry center; the coronary heart disease risk factor center; and a gross morphology
center. The morphometry central laboratory was located at Ohio State University.
Administration and coordination were directed from the University of Chicago and the
University of Illinois.
In addition to serving as collection centers, many of the centers carried out individual
research projects. At the University of Alabama in Birmingham, two separate but related
investigations were conducted: Dr. Miller analyzed the various collagens by solubilizing
them as peptide fractions and isolating the peptides via chromatography; Dr. Gay used
monoclonal antibodies to define the distribution of the various collagens in atheromatous
lesions. At the West Virginia University under Dr. Jagannathan, there were studies on
isomeric fatty acids and proteoglycans. Dr. Reichenbach at the University of Washington
studied the distribution of immunocytochemical markers of smooth muscle cell differentiation
and leukocyte subpopulations in the coronary arteries as well as searched for viral DNA in
plaques. At Baylor, the three-dimensional distribution of lipid inclusions, macrophages, and
smooth muscle cells in coronary arteries were determined by digital fluorescence. Dr.
Mergner of the University of Maryland collected specimens in the immediate autopsy program
which provided specimens free of autolysis. He also performed transmission and scanning
electron microscopy, X-ray microanalysis, lipid analysis, and immunofluorescence and
immunoperoxidase procedures to define calcium content and cytoskeletal components. Dr.
Virmani at Vanderbilt determined the role of biogenic amines such as histamine, serotonin,
and catecholamines in atherosclerosis and correlated the content of amines with the presence
of mast cells in the adventitia.
In 1988, two regular research grants were awarded as part of this multicenter study. The
grant at the Southwest Foundation for Biomedical Research determined the genotypes for each
subject with respect to restriction fragment length polymorphisms in apolipoprotein and LDL
receptor genes using Southern blot analyses of DNA from liver samples sent from each
collection center. It also typed the subjects for apo E isoform genotypes using
oligonucleotide probes. The grant at Ohio State University correlated 3-D coronary axial
geometry and pathology.
Some of the major questions addressed by the study included: whether some or all fatty
streaks progressed to fibrous plaques and the transitional lesions; the morphometric and
biochemical lesion changes indicated by progression; the frequency and features of
insudative and proliferative lesions which may portend progressive disease; sex differences
in lesions; whether immune complexes or viral infections were implicated.
In FY 1991, six grants were awarded under the title "Risk Factors in Early Human
Atherogenesis" (RFEHA). The purpose was to extend the ongoing PDAY and to : obtain an
adequate number of female cases so that risk factor associations could be accurately
detected and studied; to increase the power of the study in general to detect associations
of risk factors with raised lesions, which began to appear in this age group; and to
increase the power of the study to detect genetic influences on atherosclerosis. REFHA added
1,400 new specimens to the 1,800 cases already collected in PDAY to achieve approximately
3,000 total specimens. Emphasis was placed on female cases and those that provided the best
opportunity to study transition lesions between fatty streaks and fibrous plaques.
In 1998, the NHLBI awarded R24HL60808 for five years to provide and maintain an archive of
human cardiovascular and other tissues which can be used by other United States and
international investigators to study human atherosclerosis. The investigators, as part of
PDAY and RFEHA, have assembled autopsy material (mostly of aorta and coronary artery, but
with other tissues including liver, serum, and adipose tissue) from over 3,000 Black and
white males and females. These were from autopsies on individuals ages 15 to 34 and obtained
within 48 hours of death. The grant for the cardiovascular specimen and data library was
renewed through July 2007.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|